Meckler Jeffrey A's Form 4 filing
Travere Therapeutics, Inc. (TVTX) · filed Sep 11, 2026
- Accession no.
- 0001506916-26-000004
- Filed
- Sep 11, 2026, 4:05 PM ET
- Trade date
- Sep 10, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 6 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.35M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Meckler Jeffrey ACIK 0001506916 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 10, 2026 | Common Stock | MOption exerciseAcquired | +10,000 | $17.44 | +$174,400 | 101,500 | Direct | |
| Sep 10, 2026 | Common Stock | MOption exerciseAcquired | +10,000 | $26.52 | +$265,200 | 111,500 | Direct | |
| Sep 10, 2026 | Common Stock | SSaleDisposed | −1,700 | $65.39F2 | −$111,165.89 | 109,800 | Direct | |
| Sep 10, 2026 | Common Stock | SSaleDisposed | −1,200 | $66.15F3 | −$79,380 | 108,600 | Direct | |
| Sep 10, 2026 | Common Stock | SSaleDisposed | −14,000 | $67.46F4 | −$944,487.6 | 94,600 | Direct | |
| Sep 10, 2026 | Common Stock | SSaleDisposed | −3,100 | $68.09F5 | −$211,072.8 | 91,500 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 10, 2026 | Common Stock | MOption exerciseDisposed | −10,000 | $0.00 | $0 | 0 | Direct | |
| Sep 10, 2026 | Common Stock | MOption exerciseDisposed | −10,000 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The weighted average sale price for the transaction reported was $65.3917, and the range of prices were between $64.835 and $65.81. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
Referenced by the price of 1 transaction in Table I.
- F3
The weighted average sale price for the transaction reported was $66.15, and the range of prices were between $65.93 and $66.74. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
Referenced by the price of 1 transaction in Table I.
- F4
The weighted average sale price for the transaction reported was $67.4634, and the range of prices were between $66.93 and $67.92. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
Referenced by the price of 1 transaction in Table I.
- F5
The weighted average sale price for the transaction reported was $68.088, and the range of prices were between $67.94 and $68.23. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
Referenced by the price of 1 transaction in Table I.